Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.

By M. Hegi, Lili Liu, J. Herman, R. Stupp, Wolfgang Wick, Michael Weller, M. Mehta, M. Gilbert. Journal of Clinical Oncology, 2008

818 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Survival in glioblastoma: a review on the impact of treatment modalities (2016, background): “MGMT promotor methylation is a confirmed prognostic factor of improved survival and may also be predictive of chemotherapy responsiveness in GBM patients [10, 81], including the elderly [82].”
Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. (2010, background): “Hypermethylation of the MGMT promoter-associated CpG island has been shown in a large percentage of GBM patients (Esteller et al., 2000; Esteller et al., 1999; Hegi et al., 2005; Hegi et al., 2008; Herman and Baylin, 2003).”
MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010, neutral): “analysis, at the level of mRNA or protein expression, or by enzyme activity—and which specific procedure is best suited for routine clinical applications.(18,19) A biomarker test for”